• Kallikrein amplifies contact activation and is a potential target for preventing thrombosis.
Introduction
Prekallikrein, a single-chain monomeric glycoprotein and the inactive precursor of the serine protease plasma kallikrein, is an important component of many biological systems, including the contact activation system (CAS) [1] , the kallikrein-kinin system (KKS) [2] , the renin-angiotensin system [3] , the fibrinolytic system [4] , and the alternative complement pathway [5] . Disease states associated with aberrant prekallikrein/kallikrein activity include thrombosis, hereditary angioedema (HAE), diabetic retinopathy, intracerebral hemorrhage, and septicemia [4, 6, 7] .
The CAS is composed of prekallikrein, factor XII (FXII), factor XI (FXI) and high molecular weight kininogen (HK) [8, 9] . At the amino acid level, prekallikrein is 58% homologous to FXI, and both proteins circulate in non-covalent complexes with HK [10] [11] [12] . The CAS is activated when a small amount of FXII is converted to activated FXII (FXIIa) via contact with a negatively charged surface [8] . Prekallikrein and FXI, both anchored to the contact surface by HK, are then cleaved by FXIIa, resulting in kallikrein and activated FXI (FXIa) formation, respectively [13, 14] . CAS-generated kallikrein subsequently activates additional FXII to produce FXIIa in a feedback loop known as reciprocal activation [13] , whereas FXIa generation triggers a series of proteolytic cleavage reactions that ultimately result in thrombin generation and thrombus formation [8] . Despite their importance to the contact pathway in vitro, deficiencies in FXII, prekallikrein and HK do not manifest with a bleeding phenotype [8] . These observations led to the hypothesis that the CAS is not required for hemostasis, but may play a central role in thrombosis in vivo [15] . In vivo CAS-knockout mouse models were protected from occlusion in arterial and venous thrombosis models without a significantly increased bleeding risk [16] [17] [18] . Targeting CAS components for anticoagulant development may therefore provide a safer alternative to FX-targeted and thrombin-targeted anticoagulants, which induce a significant bleeding risk [19] .
Prekallikrein, kallikrein and HK are also important components of the KKS. Single-chain HK serves as an endogenous substrate for kallikrein cleavage, releasing the inflammatory nonapeptide bradykinin (BK) [20] . Whereas KKS activation and BK release can result from CAS activation, prekallikrein can also be activated by other activators, such as prolylcarboxypeptidase, heat shock protein 90, and polyphosphates [21] [22] [23] [24] .
Kallikrein activity in vivo is regulated by C1-esterase inhibitor (C1-inh), and C1-inh replacement therapy is used clinically to treat HAE. However, C1-inh infusion poses a risk of thromboembolic events [25] . Other kallikrein inhibitors have been described, including soybean trypsin inhibitor (SBTI) [26] , ecallantide [27] , and DX-2930 [28] , and are mainly active site inhibitors developed for HAE treatment. Interestingly, very few of these inhibitors have been explored as anticoagulants [29] , even though prekallikrein-deficient mice are protected against thrombosis [16, 30] .
Because of the central roles of both prekallikrein and kallikrein in the CAS and the KKS, we sought to develop and characterize a high-affinity RNA aptamer inhibitor of both proteins [31] . We hypothesized that targeting prekallikrein/kallikrein with an aptamer could provide an alternative mechanism of inhibition to the previously developed kallikrein active site inhibitors, as coagulation factor aptamers typically block macromolecular interactions [31, 32] . Additionally, aptamer activity can be rapidly modulated by a complementary antidote sequence or universal antidote, resulting in an improved safety profile [33, 34] .
We identified an RNA aptamer, Kall1-T4, which has potent anticoagulant effects via inhibition of reciprocal activation of prekallikrein by primarily blocking FXIIamediated prekallikrein activation. Additionally, Kall1-T4 reduces HK cleavage and BK release, and thus may represent an anti-inflammatory agent. We have developed a highly specific and potent agent that targets prekallikrein/ kallikrein and works at the interface between coagulation and inflammation.
Experimental procedures

Materials
Prekallikrein, kallikrein, HK, a-FXIIa, corn trypsin inhibitor (CTI) and chromogenic substrates (Pefachrome PK and Pefachrome 6017) were from Enzyme Research Laboratories (South Bend, IN, USA), FXII, FXIa, activated factor IX (FIXa) and activated factor II (FIIa) were from Haematologic Technologies (Essex Junction, VT, USA), SBTI was from ATCC (Manassas, VA, USA), PEG-8000 was from Fluka Biochemika (Buchs, Switzerland), and dextran sulfate was from Pharmacia Biotech (Piscataway, NJ, USA). Human pooled normal and prekallikrein-deficient plasmas were from George King Bio-Medical (Overland Park, KS, USA), HK-depleted plasma was from Affinity Biologicals (Ancaster, Canada), TriniCLOT aPTT S and PT Excel reagents were from Trinity Biotech (Bray, Co Wicklow, Ireland), APTT-XL reagent was from Thermo Scientific (Waltham, MA, USA), and CK Prest 5 (kaolin reagent) was from Diagnostica Stago (Parsippany, NJ, USA), long chain polyphosphate was from Kerafast Inc (Boston, MA, USA).
Aptamer generation
Convergent Systematic Evolution of Ligands by Exponential Enrichment (SELEX) was performed as previously described [34, 35] . Briefly, a 2ʹ-fluoro pyrimidine RNA library was generated by in vitro transcription with a modified T7 polymerase (Y639F), and selection was performed against human plasma in HEPES-based buffers. After five rounds of selection to the plasma proteome, four rounds of SELEX were performed against purified kallikrein. The fourth round was cloned and sequenced with standard methods as previously described [35] . All RNA sequences used in subsequent experiments were transcribed and purified as previously described [35] , and were refolded prior to use by heating to 65°C for 5 min, and then placed at room temperature for 3 min in the specified reaction buffer.
Nitrocellulose filter-binding assay
A double-filter nitrocellulose-binding assay was used to determine the apparent binding affinity (K d ) of c 32 Plabeled aptamer to protein as previously described [34, 35] . The bound and unbound aptamers were separated by passing the mixture over a nitrocellulose filter (Protran BA 85; GE Healthcare Piscataway, NY, USA) overlaid on a nylon filter (Gene Screen Plus; Perkin Elmer Waltham, MA, USA), and the fraction of bound versus unbound aptamer was quantified with a Storm 825 phosphorimager (GE Healthcare). Data were fitted with a non-linear regression for one-site binding by the use of GRAPHPAD PRISM, and the apparent K d was calculated.
Plasma clotting assays
Blood samples were drawn from normal, healthy volunteers in accordance with the Duke University Institutional Review Board. After discarding of the initial 3 mL, blood was collected into a syringe preloaded with CTI, and slowly dripped into a citrated tube such that the final blood concentrations of citrate and CTI were 11 mM and 50 lg mL
À1
, respectively. The CTI concentration used is sufficient to inhibit FXIIa formed during the plasma preparation, but also allows for robust FXII activation upon addition of activated partial thromboplastin time (APTT) activators [36] . Plasma was collected and stored at À 80°C until use.
APTT and prothrombin time (PT) assays were performed on a STart4 coagulometer. For both assays, RNAs were diluted into a HEPES-based buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 ) and refolded. For APTT and PT assays, RNA (5 lL) was added to plasma (50 lL) and incubated for 5 min at 37°C. For APTT, 50 lL of TriniCLOT aPTT S reagent (micronized silica), ellagic acid or kaolin reagent was added to a plasma/RNA mixture and incubated at 37°C for the time indicated. Clotting was initiated with 25 mM CaCl 2 (50 lL) for APTT and with TriniCLOT PT Excel reagent (100 lL) for PT. Aptamer concentrations represent the final reaction concentrations.
Chromogenic assays
All of the chromogenic assays described were performed in 96-well flat-bottomed microtiter plates (Greiner Bio-One, Monroe, NC, USA) at 37°C in reaction buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 0.01% bovine serum albumin [BSA] and 0.1% PEG-8000) AE 10 lM ZnCl 2 [24] in a 100-lL final reaction volume. Aptamer and protein concentrations represent final reaction concentrations, and substrate cleavage was measured at 405 nm at 37°C with a SpectraMax i3 multimode microplate reader (Molecular Devices). All measurements were performed in duplicate and repeated at least three times. Data were analyzed with SOFTMAX PRO (Molecular Devices, Sunnyvale, CA, USA) and GRAPHPAD PRISM, and fitted to linear and/or non-linear regression analysis unless indicated otherwise.
Kallikrein small-peptide substrate cleavage MichaelisMenten kinetics were determined by incubating Kall1-T4 (500 nM) with human kallikrein (10 nM) for 10 min prior to adding different concentrations (0-500 lM) of kallikrein chromogenic substrate, Pefachrome PK, and monitoring substrate cleavage. The velocity for each reaction was determined by linear regression and plotted against substrate concentration, and the K m was calculated by non-linear regression analysis.
For kallikrein active site cleavage experiments, kallikrein (10 nM) was incubated with different concentrations (0-500 nM) of aptamer, mutant control or SBTI for 10 min before addition of Pefachrome PK (0.25 mM).
Reciprocal and FXIIa activation of prekallikrein Prekallikrein (10 nM) and HK (10 nM) were incubated with different concentrations (0-500 nM) of aptamer, mutant control or SBTI for 10 min. To initiate the reactions, FXII (2 nM) and dextran sulfate (2 lg mL À1 ) were added for reciprocal activation, whereas a-FXIIa (0.05 nM) was added for FXIIa-initiated activation. The reaction was incubated for 20 min, and FXIIa activity was quenched by CTI (1 lM) addition. Kallikrein formation was assessed by Pefachrome PK (0.25 mM) addition. The relative reaction rate was determined by normalizing the kallikrein formation rate for all three conditions (Kall1-T4, Kall1-T4M1, and SBTI) to the rate without inhibitor/RNA. For kinetic reactions, FXIIa activity was quenched at various time-points by CTI addition, and kallikrein formation was determined.
Kallikrein activation of FXII Kallikrein (10 nM) and HK (10 nM) were incubated with different concentrations (0-500 nM) of aptamer, mutant control or SBTI for 10 min prior to FXII (100 nM) addition. The reaction was incubated for 20 min, and kallikrein activity was quenched by SBTI addition (50 lg mL À1 ). FXIIa formation was assessed by Pefachrome 6017 (1 mM) addition. For kinetic reactions, kallikrein activity was quenched at various time-points by SBTI addition, and FXIIa formation was determined.
Prekallikrein autoactivation Prekallikrein (100 nM) and HK (100 nM) were incubated with different concentrations (0-2 lM) of aptamer or mutant control for 10 min. Long-chain polyphosphate (10 lM) was added to the reactions and incubated for 1 h. Kallikrein formation was assessed by Pefachrome PK (0.25 mM) addition. The relative reaction rate was determined by normalizing the kallikrein formation rate for both conditions to the rate without RNA.
BK release The concentration of BK released from kallikrein cleavage of HK was determined with a BK ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA). Kallikrein (1 nM) was incubated with different concentrations of folded RNAs or SBTI in reaction buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 0.01% BSA, and 0.1% PEG-8000) for 10 min at 37°C. HK (10 nM) was added, and the reaction was incubated at 37°C for 2 h in a 100-lL total reaction volume. Reactions were precipitated with ethanol at À 80°C overnight, followed by centrifugation at 10 000 9 g for 1 h at 4°C. The BK-containing supernatant was evaporated to almost complete dryness (~20 lL remained). ELISA assay buffer (400 lL) was added to each sample, and the ELISA was performed as previously described. The data were analyzed with GRAPHPAD PRISM, a BK standard curve was generated, and the values were log-transformed to generate a linear regression for the standard curve. The BK generated for each reaction condition was interpolated from the standard curve.
Statistical analysis
GRAPHPAD PRISM was used to determine all linear and nonlinear regressions unless indicated otherwise. For IC 50 determination, Kall1-T4 concentrations were logarithmically transformed by use of the equation x = log(x + 1), as an RNA concentration of zero was used in the assay.
Results
Selection and truncation of a prekallikrein/kallikrein-binding aptamer
To identify an RNA that recognizes prekallikrein and kallikrein, convergent SELEX was performed with a modified 2ʹ-fluoropyrimidine RNA library initially focused on the plasma proteome followed by further enrichment against purified kallikrein [35] . A few highaffinity species were identified, and Kall1, an 81-mer, was chosen as the lead aptamer because of its superior binding affinity (Table S1 ). We determined that full-length Kall1 bound to both prekallikrein and kallikrein with subnanomolar affinities and apparent K d values of 0.12 AE 0.01 nM and 0.26 AE 0.02 nM, respectively (Fig. 1A,B) . To determine the minimal RNA sequence required for binding and functionality, nucleotide deletions were systematically performed to obtain a final truncate of 54 nucleotides, termed Kall1-T4 (Fig. 1C) . Kall1-T4 bound to prekallikrein and kallikrein with only modestly reduced affinity (0.28 AE 0.02 nM and 0.88 AE 0.05 nM, respectively) as compared with the parent molecule (Fig. 1A,B) . A mutant control sequence obtained by mutating three nucleotides (Kall1-T4M1; Fig. 1C , gray nucleotides) retained a similar overall
Kall1-T4 predicted structure while no longer binding to both prekallikrein and kallikrein (Fig. 1A,B) . In addition to binding with high affinity, Kall1-T4 also showed specificity for prekallikrein and kallikrein, showing little to no binding (apparent K d > 1 lM) to other coagulation proteins (HK, FXIIa, FXIa, activated FIX [FIXa] , and activated FII) even at very high protein concentrations (Fig. S1) . Each of the coagulation proteins tested was either functionally similar to kallikrein (serine proteases such as FXIa, FIXa, and thrombin) or underwent macromolecular interactions with prekallikrein and/ or kallikrein (such as FXIIa and HK). The specificity data indicated that Kall1-T4 bound to a particular region of both prekallikrein and kallikrein with > 1000-fold selectivity over related coagulation proteins.
Kall1-T4 has anticoagulant activity
To determine the anticoagulant potential of Kall1-T4 in plasma, we performed a clinical coagulation assay, i.e. APTT, using micronized silica to activate the contact pathway. Kall1-T4 dose-dependently increased the APTT clotting time of CTI-citrated plasma as compared with the mutant RNA, Kall1-T4M1 (Fig. 2) , with a seven-fold increase over baseline at 4 lM Kall1-T4. As expected, both RNAs (Kall1-T4 and T4M1) showed no effect in the PT clotting assay, which activates via the extrinsic pathway by using tissue factor (Fig. 2) . These results indicate that Kall1-T4 prolongs clotting time by inhibiting thrombin generation via a contact pathway-specific protein.
Kallikrein aptamer does not inhibit active site function
To determine whether Kall1-T4 inhibits small-substrate binding to and the enzymatic function of kallikrein's active site, we incubated kallikrein with a small chromogenic substrate and different concentrations of Kall1-T4, Kall1-T4M1, and SBTI (a known kallikrein active site inhibitor) [26] . In the presence of Kall1-T4 or Kall1-T4M1, cleavage of the small chromogenic substrate occurred, whereas SBTI dose-dependently inhibited cleavage of the same substrate (Fig. 3) . Additionally, the presence of Kall1-T4 or Kall1-T4M1 did not prevent dose-dependent SBTI inhibition of kallikrein active site function in the absence or presence of HK (Fig. S2) . These results indicate that Kall1-T4 does not bind to and block kallikrein's active site or impact on active site function in an allosteric manner. Thus, the observed anticoagulant activity of Kall1-T4 is probably attributable to inhibition of macromolecular substrates and/or cofactor binding to prekallikrein and/or kallikrein, and this mechanism of action would be consistent with that of previously described aptamers to coagulation factors (thrombin, prothrombin, factor X, FIXa, and FXII) [31, 32, [37] [38] [39] .
Aptamer-mediated inhibition of reciprocal activation of prekallikrein
In plasma, FXIIa activates prekallikrein, resulting in the formation of kallikrein, which then serves to amplify FXIIa generation by activating FXII in a feedback loop known as reciprocal activation (Fig. 4A) [8] . Prekallikrein can also be autoactivated to form kallikrein independently of FXIIa in the presence of negatively charged surfaces and long-chain polyphosphates [24] . The ability of Ratio of RNA or SBTI to kallikrein Relative rate of kallikrein substrate cleavage Fig. 3 . Kall1-T4 does not inhibit kallikrein cleavage of a small chromogenic substrate. Varying concentrations of Kall1-T4 (■), Kall1-T4M1 (•) and SBTI (▲) were incubated with kallikrein, and cleavage of the substrate was monitored. The data were normalized to the rate of substrate cleavage in the absence of RNA or soybean trypsin inhibitor (SBTI), and represent the mean AE standard deviation of at least three independent experiments.
Kall1-T4 to inhibit this feedback loop was examined by assessing the rate of kallikrein generation and the amount of kallikrein generated in the absence and presence of either Kall1-T4 or the kallikrein active site inhibitor SBTI. This purified protein assay uses FXII and stoichiometric equivalents of prekallikrein and HK, and is activated by dextran sulfate addition. Dextran sulfate preferentially induces FXII autoactivation [40] , generating small amounts of FXIIa, which activates prekallikrein to form kallikrein. As a consequence, significant kallikrein formation in this assay requires concurrent FXIIa generation via the reciprocal activation feedback loop. Kall1-T4 significantly and dose-dependently decreased reciprocal kallikrein amplification by > 90% in comparison with equivalent concentrations of the control RNA, Kall1-T4M1, and at similar levels to the SBTI-induced dosedependent decrease in kallikrein activity (Fig. 4B) . We subsequently determined an IC 50 value for Kall1-T4 inhibition for the reciprocal activation reaction of 18.5 nM (Fig. 5A) , which is similar to the IC 50 value obtained in the absence of HK (13 nM; Fig. S3 ).
To further explore the mechanism of Kall1-T4 inhibition of reciprocal activation, we used a purified protein system to test the inhibition of FXIIa-mediated prekallikrein activation, and determined the rate of kallikrein formation and the amount of kallikrein formed in the absence and presence of different concentrations of Kall1-T4. Kall1-T4 dose-dependently decreased FXIIa activation of prekallikrein by > 85% in comparison with the control mutant aptamer (Kall1-T4M1), and we observed a similar decrease in kallikrein generation in the presence of varying SBTI concentrations (Fig. 4C) . We determined an IC 50 of 11.4 nM for Kall1-T4 inhibition of FXIIamediated prekallikrein activation (Fig. 5B) , which is similar to the IC 50 value (18.5 nM) obtained for inhibition of the reciprocal activation reaction. We also assessed the effect of zinc ions on Kall1-T4 inhibition of reciprocal activation, as it has been suggested that some contact reactions require zinc ions for maximal activity. In the presence of 10 lM ZnCl 2 , we observed only a modest two-fold increase in the IC 50 value (18.5 nM versus 35.1 nM; Fig. S4 ).
To further characterize the kinetics of Kall1-T4-mediated inhibition of FXIIa-dependent prekallikrein activation, we next determined a Michaelis constant (K m ) of 188.7 AE 15 lM for kallikrein cleavage of the chromogenic substrate in the presence of Kall1-T4 (data not shown). Using this K m , we obtained an apparent equilibrium inhibition constant (K i ) of 1.4 nM (Fig. 5D) , which is approximately eight-fold lower than the IC 50 (11.4 nM) determined for Kall1-T4 inhibition of FXIIa-mediated prekallikrein activation (Fig. 5B) . However, the K i obtained is much closer to the apparent K d of Kall1-T4 binding to prekallikrein (0.28 nM), and is probably a more accurate representation of the inhibition kinetics than the IC 50 values.
We then examined the effect of Kall1-T4 on prekallikrein autoactivation in the presence of long-chain polyphosphates [24] . We observed a similar dose-dependent decrease in kallikrein formation in the presence of Kall1-T4 in comparison with control RNA (Fig. 4D) . We determined an IC 50 value of 167 nM for the reaction (Fig. 5C ), which is 10-fold higher than that obtained for both the reciprocal and FXIIa-mediated prekallikrein activation. This result was unsurprising, as we had to use a 10-fold greater concentration of prekallikrein and HK to observe appreciable autoactivation in this assay.
Finally, we assessed the effect of Kall1-T4 on kallikrein-mediated FXII activation. We observed an initial 40% decrease in the rate of FXIIa generation at low concentrations of Kall1-T4 (6.25-25 nM) as compared with control RNA Kall1-T4M1 (Fig. 4E) . This decreased rate of FXIIa generation remained constant even in the presence of much higher concentrations of Kall1-T4. Taken together, the data suggest that Kall1-T4 inhibits reciprocal activation in a concentration-dependent manner primarily through inhibition of FXIIa-mediated prekallikrein activation. Although there may be a small contribution from the inhibition of kallikrein-mediated FXII activation, the lack of concentration dependence suggests that this mode of inhibition is secondary.
Aptamer-mediated inhibition of HK cleavage and BK release
In addition to propagation of thrombin generation via reciprocal activation, plasma kallikrein is also involved in activating the innate immune response via BK liberation (Fig. 4A) . To determine whether Kall1-T4 has an effect on HK cleavage, we tested various Kall1-T4 concentrations (0-500 nM) in a kallikrein-mediated BK release assay. Kall1-T4 dose-dependently reduced BK release, with a decrease of up to~65% being observed at the highest Kall1-T4 concentrations tested (250-500 nM) (Fig. 6A) . We then directly compared the amounts of BK released when specific concentrations of Kall1-T4, Kall1-T4M1 and SBTI were used (Fig. 6B) . As compared with a control reaction without inhibitor or RNA, Kall1-T4 and SBTI at concentrations of 50 nM and 500 nM significantly decreased HK cleavage and BK release. Specifically, 50 nM Kall1-T4 decreased BK release by~33% (P < 0.01), and the equivalent SBTI concentration resulted in decrease of~25% (P < 0.05). Greater inhibition of BK release was observed at the higher concentrations of Kall1-T4 and SBTI, with~65% and~70% inhibition, respectively, as compared with control (P < 0.001). In contrast, the mutant aptamer did not result in a significant change in BK release.
Discussion
The relative importance of the contact pathway in hemostasis and thrombosis has long been debated, and it ) were incubated with (B) prekallikrein and high molecular weight kininogen (HK) prior to addition of FXII and dextran sulfate to initiate FXII activation, (C) prekallikrein and HK prior to addition of purified a-FXIIa, (D) prekallikrein and HK prior to addition of long-chain polyphosphate, and (E) kallikrein and HK prior to addition of FXII. For (B), (C) and (D), the reaction rate represents the rate of cleavage of the kallikrein substrate by the kallikrein generated during the reaction; for (E), the reaction rate represents the rate of cleavage of the FXIIa substrate by the FXIIa generated during the reaction. The relative rate of kallikrein activity was obtained by normalizing each rate to the rate of substrate cleavage in the absence of RNA or SBTI, and represents the mean AE standard deviation of at least three independent experiments. is thought to be a possible surface-activated defense system [1] . Interest in FXII inhibitors has increased recently, owing to many studies highlighting the fact that FXIIa inhibition provides protection against arterial and venous thrombosis without a significant increase in bleeding [16, 41] . Other studies have indicated that inhibition of other contact pathway mediators, such as kallikrein and HK, may also provide protection against thrombosis in vivo [16] . As most of the current kallikrein inhibitors target and block active site cleavage, and serine protease specificity in coagulation is mainly derived from the macromolecular interactions at exosites [15, 42] , we sought to develop an exosite-targeting aptamer that could bind to and inhibit both prekallikrein and kallikrein.
Here, we describe the development and characterization of a novel prekallikrein/kallikrein-targeting RNA aptamer that has both anticoagulant and anti-inflammatory activities (Fig. 4A) . The Kall1-T4 aptamer binds to prekallikrein, preventing thrombin generation via inhibition of reciprocal activation of prekallikrein and FXII, primarily by inhibiting FXIIa-mediated prekallikrein activation. Additionally, Kall1-T4 binds to kallikrein and reduces HK cleavage and BK release without inhibiting active site function.
Kall1-T4 treatment of CTI-citrated plasma results in potent anticoagulation (Fig. 2) . Despite circulating as a complex with HK, these results are probably not HKdependent, as Kall1-T4 also dose-dependently increases the clotting time of HK-depleted plasma (Fig. S5A) . Prekallikrein-deficient plasma shows different APTT clotting times with different APTT reagents, with silica reagent resulting in a prolonged clotting time, and ellagic acid normalizing clotting time [30, 43] . We compared all three activation reagents in prekallikrein-deficient plasma, and only observed prolongation of clotting time with the silica reagent (Fig. S5B) . We also observed that Kall1-T4 does not prolong the clotting time in an ellagic acid-triggered or kaolin-triggered APTT assay using CTI-citrated plasma (Fig. S5C ). This observation is also consistent with the notion that the relative contribution of prekallikrein to coagulation in the APTT assay is dependent on the reagent used to initiate FXII activation [43, 44] . Interestingly, we observed no clotting time prolongation in normal citrated plasma upon treatment with Kall1-T4 (Fig. S6) , which suggests that contact pathway activation occurs during normal plasma preparation and produces sufficient FXIIa to bypass the anticoagulant effects of Kall1-T4. Consistent with this observation, activation of CTI-citrated plasma with FXIIa also bypasses the anticoagulant effect of Kall1-T4 (data not shown). Although Kall1-T4 effectively and dose-dependently blocks FXIIa-mediated prekallikrein activation, Kall1-T4 has only a small effect (~40% decrease) on kallikreinmediated FXII activation. One explanation for this observation is that FXII easily undergoes autoactivation on artificial surfaces and in the presence of many biological substances [45] . FXII autoactivation could account for the FXIIa activity observed in the presence of both Kall1-T4 and SBTI. Another explanation for incomplete Kall1-T4 inhibition of kallikrein-mediated FXII activation is that our current assay was not sensitive enough to detect complete inhibition of FXII activation, as SBTI at 2.5 lM (a concentration that should produce almost complete inhibition [26] ) resulted in a decrease of FXII activation in this assay of only~65% (data not shown).
The mechanism of Kall1-T4 suggests that the aptamer binds to a specific patch on prekallikrein that is involved in macromolecular contacts with FXIIa, and this site may either be in close proximity to or induce allosteric changes in the HK-binding site. As Kall1-T4 binds to both prekallikrein and kallikrein with relatively similar affinities, and prekallikrein conversion to kallikrein results in active site conformational changes, the Kall1-T4-binding site is less likely to be located on the light chain containing the active site. Given that HK does not appear to compete with Kall1-T4 for binding on prekallikrein or kallikrein (data not shown), and that prekallikrein homology modeling suggests that the FXIIa-binding site is located on the heavy chain of prekallikrein [46] , we hypothesize that Kall1-T4 binds to the heavy chain of both prekallikrein and kallikrein at an exosite that prevents FXIIa binding. On the basis of previous aptamer-protein crystal structures, in which aptamer-binding sites have mostly been confined to basic patches on the target proteins [31] , Kall1-T4 probably binds to a basic surface on kallikrein, which allosterically reduces HK binding and/or cleavage.
Further testing of Kall1-T4 in vivo would be required in order to determine its potency as an anticoagulant. Targeting prekallikrein/kallikrein could provide therapeutic value, as studies have shown that prekallikrein- Percentages of BK release in the presence of Kall1-T4, control aptamer and soybean trypsin inhibitor (SBTI) at 50 nM and 500 nM were compared with a control reaction without inhibitor or RNA. For both (A) and (B), the amount of BK generated was quantified with a BK ELISA, and percentage BK release was calculated by normalizing the amount of BK produced for each reaction condition to the amount of BK produced in the absence of RNA or inhibitor. The data are represented as the mean AE standard error of the mean of at least three independent experiments, and the data were analyzed by one-way ANOVA, with Dunnett's post hoc test being used to adjust for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. deficient mice are protected from occlusion after FeCl 3 -induced or Rose Bengal-induced vessel injury [17] . However, FXIIa active site inhibition more effectively prevented occlusion than did kallikrein active site inhibition in vivo [17] . In light of these studies, Kall1-T4 may not be as potent as an FXIIa inhibitor to prevent thrombosis in vivo, especially in instances where robust anticoagulation is required. One solution would be to pair the kallikrein-targeting aptamer with the previously developed FXII/FXIIa-targeting aptamer, R4cXII-1t, either separately or by linking them to create a bivalent aptamer [39, 47] . As R4cXII-1t inhibits FXII autoactivation and FXIIa-mediated FXI activation, combining both aptamers would effectively eliminate the initiation of the contact pathway in vivo and provide a viable option for the safe prevention of thrombosis.
Addendum K-A. Steen Burrell designed and performed research, analyzed data, and wrote the manuscript. J. Layzer performed research, analyzed data, and wrote the manuscript. B. A. Sullenger designed and coordinated research, analyzed data, and wrote the manuscript.
Acknowledgements
This work was supported in part by NIH grant R01 HL065222 (B. A. Sullenger).
Disclosure of Conflict of Interests
B. A. Sullenger reports being a founder and equity holder of Regado Biosciences/Tobira, outside the submitted work. All authors have a patent submission pending.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 . Kall1-T4 binds with high specificity to kallikrein. Fig. S2 . SBTI inhibition of kallikrein active site function in the absence or presence of Kall1-T4, Kall1-T4M1 and/ or HK Fig. S3 . Effects of HK on reciprocal activation. Fig. S4 . Effect of Zn 2+ ions on Kall1-T4 inhibition of reciprocal activation. Fig. S5 . Effects of Kall1-T4 and different reagents in HK-depleted, prekallikrein-deficient and CTI-citrated plasma. Fig. S6 . Kall1-T4 dose-dependently prolongs APTT clotting time of CTI-citrated plasma, but not of citrated plasma. Table S1 . Kall1, truncated Kall1-T4 and mutant control Kall1-T4M1 RNA sequences.
